Skip to main content

Table 3 Summary of efficacy data from phase II/III trials of emerging anti-angiogenic agents in recurrent ovarian cancer

From: Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review

Study (n) Regimen ORR (CR + PR), % Median PFS, months Median OS, months
Matulonis et al. [42] Cediranib 45 mg/day 17 5.2 Not reached
(n = 46)
Ledermann et al. [43] Cediranib 20 mg/day → cedarinib maintenance vs. placebo Restricted mean survival time, months Restricted mean survival time, months
(n = 456) 11.4 vs. 9.4 20.3 vs. 17.6
Du Bois et al. [44] Pazopanib 800 mg/day vs. placebo 17.9 vs. 12.3 Not reached
(n = 940)
Campos et al. [45] Sunitinib 37.5 mg/day 8.3 9.9b
(n = 35)
Biagi et al. [46] Sunitinib 50 mg/day (int.) 13.3 4.1
(n = 30)
Baumann et al. [47] Sunitinib 50 mg/day (int.) vs. 37.5 mg/day (cont.) 16.7 vs. 5.4 4.8 vs. 2.9 13.6 vs. 13.7
(n = 73)
Matei et al. [48] Sorafenib 400 mg b.i.d. 3.4 6-month PFS rate: 24%
(n = 71)
Herzog et al. [49] Sorafenib 400 mg b.i.d. vs. placebo 386 vs. 478a
(n = 249)
Ledermann et al. [50] Nintedanib 250 mg b.i.d. vs. placebo 36-week PFS rate:
(n = 83) 16.3% vs. 5.0%
Du Bois et al. [51] Nintedanib 200 mg b.i.d. + CP vs. nintedanib + placebo 17.3 vs. 16.6
(n = 1,366)
Coleman et al. [52] Aflibercept 6 mg/kg + D 54 6.2 24.3
(n = 46)
Gotlieb et al. [53] Aflibercept 4 mg/kg vs. placebo 6.3 vs. 7.3b 12.9 vs. 16.0b
(n = 55)
Colombo et al. [54] Aflibercept 4 mg/kg 8.5b
(n = 16)
Karlan et al. [55] Trebananib 10 mg/kg + P vs. trebananib 3 mg/kg + P vs. placebo + P 37 vs. 19 vs. 27 7.2 vs. 5.7 vs. 4.6 22.5 vs. 20.4 vs. 20.9
(n = 161)
Monk et al. [56] Trebananib 15 mg/kg + P vs. placebo + P 38 vs. 30 7.2 vs. 5.4 19.0c vs. 17.3c
(n = 919)     
  1. b.i.d. = twice daily. cont = continuous. CR = complete response. D = docetaxel. int = intermittent. ORR = objective response rate. OS = overall survival. PFS = progression-free survival. P = paclitaxel. PR = partial response.
  2. aTime in days.
  3. bTime in weeks.
  4. CInterim data.